

## **TB THEN AND NOW: LOOKING BACK, LOOKING FORWARD**

**MARCH 26, 2018**

**CME/CE CERTIFIED ACTIVITY**

### **Course Location**

**Farkas Auditorium, NYU Langone Medical Center  
550 First Avenue  
New York, NY 10016**

### **Jointly Provided By**

**Global Tuberculosis Institute at Rutgers, The State University of New Jersey, New York City Department of Health and Mental Hygiene, NYU School of Medicine, NYC Health and Hospitals/Bellevue**

The Global Tuberculosis Institute at Rutgers is the tuberculosis Center of Excellence for the northeastern United States

*This activity is supported in part by an educational grant from the Centers for Disease Control and Prevention, Division of Tuberculosis Elimination*

## **WHY COURSE IS NEEDED**

As the incidence of TB continues to decline, maintaining clinical expertise is particularly challenging especially as the cases are more complex to diagnose and manage. Ongoing training and education are important for clinicians so they can develop and enhance skills in the diagnosis of TB, follow recommended treatment guidelines, and interact effectively with public health agencies.

## **COURSE DESCRIPTION & OVERALL GOAL**

In commemoration of World TB Day, this conference will address the history of the TB epidemic in New York City and the path towards TB elimination. Topics will include a review of local epidemiology, infectiousness and transmission of TB, short-course regimens for MDR TB, emerging drugs for TB treatment and strategies for addressing the current state of TB in New York City.

## **COURSE REQUIREMENTS**

In order to meet the learning objectives and receive continuing education credits, participants are required to attend the entire training and complete an evaluation. Participants will be asked to complete a follow-up evaluation within 1 month of the training.

## **WHO SHOULD ATTEND**

This conference is open to physicians, nurses, epidemiologists, researchers and students, as well as other health care workers who manage patients at risk for or diagnosed with TB infection or disease.

## **OBJECTIVES**

Upon completion of this workshop, participants should be better able to:

- Recognize the epidemiology of tuberculosis in New York City to make informed decisions about outreach interventions and allocation of resources.
- Apply current approaches for the management of drug resistant TB.
- Compare new and emerging medications with previous drug regimens to provide improved TB treatment to patients.

- Explain the role between TB treatment and infectiousness of patients, and infection control measures used to reduce the risk of transmission.
- Outline strategies for TB elimination, including efforts for expanded testing and treatment of person with TB infection.

## FACULTY LIST

### **Shama Ahuja, PhD, MPH**

Director, Office of Surveillance and Epidemiology  
New York City Department of Health & Mental Hygiene, Bureau of TB Control

### **Joseph Burzynski, MD**

Assistant Commissioner/Director  
New York City Department of Health & Mental Hygiene, Bureau of TB Control

### **Charles Daley, MD**

Chief, Division of Mycobacterial & Respiratory Infections  
National Jewish Health

### **Thomas R. Frieden, MD, MPH**

President & Chief Executive Officer  
Vital Strategies

### **Mengchun Li, MD**

Clinical Safety Officer  
TB Alliance

### **Edward Nardell, MD**

Professor of Medicine  
Harvard Medical School

### **Kate O'Brien**

Patient Advocate

### **Nauman Rana**

Patient Advocate

### **Lee Reichman, MD**

Senior Advisor  
Global Tuberculosis Institute

## PLANNING COMMITTEE

### **Global Tuberculosis Institute**

*Arpita Jindani, MSW, MA - Health Educator*  
*Anita Khilall, MPH - Director of Education & Training*

### **New York University School of Medicine**

Caralee Caplan Shaw, MD - Co-Director, Bellevue Chest Clinic and Assistant Professor  
Marla Hymes - Developer of External Affairs

### **New York City Department of Health & Mental Hygiene, Bureau of TB Control**

*Martha Alexander, MHS -Director of Training*  
*Elvy Barroso, MD, MSc, MSN, RN -Professional Development Coordinator*  
*Tiffany Hsu -Health Educator*  
*Shaila Rao, EdD, MPH -Director of Outreach*

## AGENDA

|          |  |
|----------|--|
| 8:00 am  | Registration   |
| 9:00 am  | Welcome & Housekeeping   |
| 9:10 am  | Course Overview  |
| 9:25 am  | Keynote: TB Then and Now-Strides We've Made in TB  |
| 10:05 am | The State of TB in New York City   |
| 11:00 am | Break  |
| 11:15 am | When Does Treatment Render TB Patients Non-infectious? Implications for Domestic and Global TB Control |
| 12:00 pm | Lunch  |
| 1:00 pm  | Treatment of MDR-TB: An Update on New Regimens   |
| 2:00 pm  | Patient Perspective  |
| 2:45 pm  | Break  |
| 3:00 pm  | Overview of the TB Alliance Drug Development Pipeline ( <i>CME/CNE credit not offered</i> )            |
| 3:30 pm  | Strategies for TB Elimination  |
| 4:30 pm  | Closing  |
| 5:00 pm  | Adjourn  |

## CONTINUING EDUCATION INFORMATION



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Rutgers Biomedical and Health Sciences, New York City Department of Health and Mental Hygiene, NYU School of Medicine, and NYC Health and Hospitals/Bellevue. Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**PHYSICIANS:** Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 5.75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**NURSES:** This activity is awarded 5.75 contact hours (60-minute CH). Nurses should only claim those contact hours actually spent participating in the activity.

## PEER REVIEW STATEMENT

In order to help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, Rutgers Biomedical and Health Sciences (RBHS) has resolved all potential and real conflicts of interest through content review by a non-conflicted, qualified reviewer. This activity has been peer reviewed for relevance, accuracy of content and balance of presentation by Arpita Jindani, MSW, MA.

## DISCLOSURE DISCLAIMER

In accordance with the disclosure policies of RBHS and to conform with Joint Accreditation requirements and FDA guidelines, individuals in a position to control the content of this educational activity are required to disclose to the activity participants: 1) the existence of any relevant financial relationship with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, with the exemption of non-profit or government organizations and non-health care related companies, within the past 12 months; and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/device not yet approved.

### Financial Disclosure

The following faculty and planning committee members have stated that they have no relevant financial relationships to disclose:

Shama Ahuja, PhD, MPH  
Martha Alexander, MHS  
Elvy Barroso, MD, MSc, MSN, RN  
Joseph Burzynski, MD, MPH  
Thomas R. Frieden, MD, MPH  
Tiffany Hsu  
Marla Hymes  
Arpita Jindani, MSW, MA  
Anita Khilali, MPH

Edward Nardell, MD  
Kate O'Brien  
Nauman Rana  
Shaila Rao, EdD, MPH  
Lee Reichman, MD

The following faculty have disclosed their relevant financial relationships:

Caralee Caplan-Shaw, MD MPH has disclosed that she is a consultant for Cohero Health which is a medical device startup that addresses asthma and COPD.

Charles Daley, MD has disclosed that he has a relationship with Otsuka Pharmaceuticals as is he is the chair of their data monitoring committee for the drug delamanid as well as with Johnson and Johnson as a member of their Scientific Advisory Board for the drug bedaquiline.

Charles Daley, MD has disclosed the following relationship with pharmaceutical firms:

**Otsuka**

- Member, Safety Monitoring Committee for delamanid pediatric MDR-TB trials (open)

**Novartis**

- Chair, Data Monitoring Committee for clofazimine MDR-TB trial (closed)

**Johnson and Johnson**

- Member, Advisory Board, NTM

Mengchun Li, MD has disclosed that she has owns stock (200 shares) in Johnson & Johnson.

RBHS Center for Continuing and Outreach Education Staff  
Elizabeth Ward, MSJ, Executive Director has no relevant financial relationships to disclose.

**Off-Label/Investigational Use Disclosure**

The talk by Charles Daley, MD will include the mention of off label use of the following drugs, flouroquinolones, delamanid, clofazimine and linezolid.

The talk by Mengchun Li, MD will include the mention use of bedaquiline and linezolid, as they are being tested as part of the treatment regimen in TB Alliance trials.

## CONTENT DISCLAIMER

The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of any manufacturer of pharmaceuticals or devices, or Rutgers. It should be noted that the recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk, are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating presenters. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult all available data or procedures before using them in clinical practice. Rutgers reserves the right to modify the activity content and faculty if necessary.

## COPYRIGHT

Copyright©2018 Rutgers, The State University of New Jersey. All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from Rutgers.

Please direct continuing education related questions to CCOE at 973-972-4267 or email [ccoe@ca.rutgers.edu](mailto:ccoe@ca.rutgers.edu).

Please direct content or course related questions to Arpita Jindani 973-972-4811 or email [arpita.jindani@rutgers.edu](mailto:arpita.jindani@rutgers.edu).